RT Journal Article
T1 Three Versus Six Months of Adjuvant Doublet Chemotherapy for Patients With Colorectal Cancer: A Multi-Country Cost-Effectiveness and Budget Impact Analysis
A1 Hanna, Catherine R.
A1 Robles-Zurita, José Antonio
A1 Briggs, Andrew
A1 Harkin, Andrea
A1 Kelly, Caroline
A1 McQueen, John
A1 Allan, Karen
A1 Pearson, Sarah
A1 Hollander, Henrik
A1 Glimelius, Bengt
A1 Salazar, Ramon
A1 Segelov, Eva
A1 Saunders, Mark
A1 Iveson, Tim
A1 Jones, Robert J.
A1 Boyd, Kathleen A.
K1 Cancer - Tratamiento
AB Background: The Short Course Oncology Treatment (SCOT) trial demonstrated non-infer ior it y, less toxicit y, and cost- effectiveness from a UK perspective of 3 versus 6 months of oxaliplatin-based chemotherapy for patients with colorectal cancer. This study assessed the cost-effectiveness of shorter treatment and the budget impact of implementing trial findings from the perspectives of all countries recruited to SCOT: Australia, Denmark, New Zealand, Spain, Sweden, and the United Kingdom. Patients and Methods: Individual cost–utility analyses were performed from the perspective of each country. Resource, quality of life, and survival estimates from the SCOT trial ( N = 6065) were used. Probabilistic sensitivity analysis and subgroup analyses were undertaken. Using undiscounted costs from these cost–utility analyses, the impact on country-specific healthcare budgets of implementing the SCOT trial findings was calculated over a 5- year period. The currency used was US dollars (US$), and 2019 was the base year. One-way and scenario sensitivity analysis addressed uncertainty within the budget impact analysis. Results: Three months of treatment were cost saving and cost-effective compared to 6 months from the perspective of all countries. The incremental net monetary benefit per patient ranged from US$8972 (Spain) to US$13,884 (Denmark). The healthcare budget impact over 5 years for the base-case scenario ranged from US$3.6 million (New Zealand) to US$61.4 million (UK) and totaled over US$150 million across all countries. Conclusion: This study has widened the transferability of results from the SCOT trial, showing that shorter treatment is cost-effective from a multi-country perspective. The vast savings from implementation could fully justify the investment in conducting the SCOT trial.
PB CIG MEDIA GROUP, LP
YR 2021
FD 2021
LK https://hdl.handle.net/10630/37223
UL https://hdl.handle.net/10630/37223
LA eng
NO Hanna, C. R., Robles-Zurita, J. A., Briggs, A., Harkin, A., Kelly, C., McQueen, J., ... & Boyd, K. A. (2021). Three versus six months of adjuvant doublet chemotherapy for patients with colorectal cancer: a multi-country cost-effectiveness and budget impact analysis. Clinical colorectal cancer, 20(3), 236-244.
NO This study was supported by a Clinical Trials Fellowship Grant from Cancer Research UK and the University of Glasgow (Grant ID: C61974/A2429 to CRH). The SCOT trial was supported by funding from the Medical Research Council; National Institute for Health Research; National Cancer Research Network/Scottish Cancer Research Network/National Institute for Health Research infrastructure funding within the participating sites in the UK; the Swedish Cancer Society; Interreg in Denmark; and Cancer Research UK Core Clini- cal Trials Unit. These funders had no role in the identification, design, conduct, and reporting of the analysis.
DS RIUMA. Repositorio Institucional de la Universidad de Málaga
RD 20 ene 2026